J P Hodge
Overview
Explore the profile of J P Hodge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heath E, Chiorean E, Sweeney C, Hodge J, Lager J, Forman K, et al.
Clin Pharmacol Ther
. 2010 Oct;
88(6):818-23.
PMID: 20980999
Pazopanib is an oral angiogenesis inhibitor of vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor receptor, and cytokine receptor. This open-label, randomized, crossover, phase I study evaluated the effect...
2.
Goh B, Reddy N, Dandamudi U, Laubscher K, Peckham T, Hodge J, et al.
Clin Pharmacol Ther
. 2010 Oct;
88(5):652-9.
PMID: 20881954
Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with...
3.
Blagden S, Molife L, Seebaran A, Payne M, Reid A, Protheroe A, et al.
Br J Cancer
. 2008 Mar;
98(5):894-9.
PMID: 18319713
The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib (SB-715992) in combination with docetaxel. Patients with advanced solid tumours...
4.
Kathman S, Williams D, Hodge J, Dar M
Clin Pharmacol Ther
. 2006 Dec;
81(1):88-94.
PMID: 17186004
The goal of the present analysis is to fit a Bayesian population pharmacokinetic pharmacodynomic (PK-PD) model to characterize the relationship between the concentration of ispinesib and changes in absolute neutrophil...
5.
Kurtzberg J, Ernst T, Keating M, Gandhi V, Hodge J, Kisor D, et al.
J Clin Oncol
. 2005 May;
23(15):3396-403.
PMID: 15908652
Purpose: A phase I study was conducted to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetics of a novel purine nucleoside, nelarabine, a soluble prodrug of 9-beta-D-arabinosylguanine (araG; Nelarabine),...
6.
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez Jr C, et al.
J Clin Oncol
. 2001 Apr;
19(8):2142-52.
PMID: 11304766
Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the prodrug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to...
7.
Kisor D, Plunkett W, Kurtzberg J, Mitchell B, Hodge J, Ernst T, et al.
J Clin Oncol
. 2000 Mar;
18(5):995-1003.
PMID: 10694549
Purpose: To characterize the pharmacokinetics of nelarabine (506U78), the water-soluble prodrug of 9-beta-D-arabinofuranosyl guanine (ara-G), and ara-G in pediatric and adult patients with refractory hematologic malignancies. Ara-G is phosphorylated within...
8.
Hodge J, Krieg N
J Appl Bacteriol
. 1994 Dec;
77(6):666-73.
PMID: 7822225
Oxygen tolerance of the microaerophile Campylobacter jejuni subsp. jejuni varied with different brands of complex media which were used for plating the dilute cell suspensions. The tryptone component was one...